Homologous Recombination Deficiency (HRD) testing helps personalize treatment for ovarian cancer by identifying tumors with impaired DNA repair mechanisms. Patients with HRD-positive tumors, including those with BRCA1/2 mutations, may benefit from targeted therapies like PARP inhibitors. This test enables oncologists to tailor treatment plans, improve outcomes, and avoid unnecessary side effects.
30 days upon receipt of sample in the lab.
Hati Health is your digital health companion that connects you with trusted clinics and doctors across the Philippines. We make booking appointments and accessing healthcare simple and convenient, all through our growing network of 100+ partners.
Read MoreWe work with a growing network of trusted clinics nationwide, making it convenient to find quality care wherever you are. Just share what service you need and your location—we'll show you all the available options nearby.
Read MoreWe offer flexible payment options including GCash, credit/debit cards, and bank transfers, with installment plans through BillEase and GoTyme. While we don't accept insurance yet, our affordable prices are often lower than HMO networks, and we're working on future partnerships.
Read MoreYou can reach us through our support chat on the website, Messenger or email us at [email protected]. Our team is here to assist you.
Read More